A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Wietske Kievit, Dirk J. de Jong et al.|Digestive Diseases and Sciences|2024Cited by 2
Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIALLisa M. van Lierop, Frank Hoentjen, F. A. R. Jansen et al.|Gastroenterology|2025Cited by 0
992: ALGORITHM-BASED INTEGRATED CARE FOR THE TREATMENT OF CHRONIC PANCREATITIS: A NATIONWIDE STEPPED-WEDGE CLUSTER RANDOMIZED CONTROLLED TRIALFlorence d. Rijk, Robert C. Verdonk, Naomi Thierens et al.|Gastroenterology|2025Cited by 0